2.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrenc...
by Sgroi, Dennis C, Prof
The lancet oncology, 2013, Vol.14 (11), p.1067-1076
3.
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
by Goss, Paul E, Prof
The lancet oncology, 2013, Vol.14 (1), p.88-96
4.
Challenges to effective cancer control in China, India, and Russia
by Goss, Paul E, Prof
The lancet oncology, 2014, Vol.15 (5), p.489-538
5.
Breast cancer in Brazil: present status and future goals
by Lee, Brittany L, MD
The lancet oncology, 2012, Vol.13 (3), p.e95-e102
6.
Breast cancer in Mexico: a growing challenge to health and the health system
by Chávarri-Guerra, Yanin, MD
The lancet oncology, 2012, Vol.13 (8), p.e335-e343
7.
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled...
by Cheung, Angela M, Dr
The lancet oncology, 2012, Vol.13 (3), p.275-284
8.
Planning cancer control in Latin America and the Caribbean
by Goss, Paul E, Prof
The lancet oncology, 2013, Vol.14 (5), p.391-436
9.
Progress and remaining challenges for cancer control in Latin America and the Caribbean
by Strasser-Weippl, Kathrin, MD
The lancet oncology, 2015, Vol.16 (14), p.1405-1438
10.
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
by Goss, Paul E, Prof
The lancet oncology, 2014, Vol.15 (4), p.474-482
11.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
by Oza, Amit M, Prof
The lancet oncology, 2015, Vol.16 (8), p.928-936
